1. Home
  2. FERA vs OLMA Comparison

FERA vs OLMA Comparison

Compare FERA & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FERA
  • OLMA
  • Stock Information
  • Founded
  • FERA 2024
  • OLMA 2006
  • Country
  • FERA Cayman Islands
  • OLMA United States
  • Employees
  • FERA N/A
  • OLMA N/A
  • Industry
  • FERA
  • OLMA Biotechnology: Pharmaceutical Preparations
  • Sector
  • FERA
  • OLMA Health Care
  • Exchange
  • FERA Nasdaq
  • OLMA Nasdaq
  • Market Cap
  • FERA 317.4M
  • OLMA 378.9M
  • IPO Year
  • FERA 2025
  • OLMA 2020
  • Fundamental
  • Price
  • FERA $10.13
  • OLMA $5.46
  • Analyst Decision
  • FERA
  • OLMA Strong Buy
  • Analyst Count
  • FERA 0
  • OLMA 5
  • Target Price
  • FERA N/A
  • OLMA $24.00
  • AVG Volume (30 Days)
  • FERA 3.0
  • OLMA 450.7K
  • Earning Date
  • FERA 01-01-0001
  • OLMA 08-11-2025
  • Dividend Yield
  • FERA N/A
  • OLMA N/A
  • EPS Growth
  • FERA N/A
  • OLMA N/A
  • EPS
  • FERA N/A
  • OLMA N/A
  • Revenue
  • FERA N/A
  • OLMA N/A
  • Revenue This Year
  • FERA N/A
  • OLMA N/A
  • Revenue Next Year
  • FERA N/A
  • OLMA N/A
  • P/E Ratio
  • FERA N/A
  • OLMA N/A
  • Revenue Growth
  • FERA N/A
  • OLMA N/A
  • 52 Week Low
  • FERA $10.00
  • OLMA $2.86
  • 52 Week High
  • FERA $10.60
  • OLMA $13.93
  • Technical
  • Relative Strength Index (RSI)
  • FERA N/A
  • OLMA 54.42
  • Support Level
  • FERA N/A
  • OLMA $5.54
  • Resistance Level
  • FERA N/A
  • OLMA $5.85
  • Average True Range (ATR)
  • FERA 0.00
  • OLMA 0.30
  • MACD
  • FERA 0.00
  • OLMA -0.01
  • Stochastic Oscillator
  • FERA 0.00
  • OLMA 51.79

About FERA Fifth Era Acquisition Corp I Class A Ordinary Shares

Fifth Era Acquisition Corp I is a blank check company.

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: